847:
Patient-reported experience on training associated with subcutaneous immunoglobulin (SCIG) therapy self-administration
Monday, March 5, 2018
South Hall A2 (Convention Center)
Tiffany S. Henderson, PHD, Rajiv Mallick, PhD, Jacob M. Romano, Christopher Scalchunes, MPA
RATIONALE: To evaluate experience of primary immunodeficiency (PI) patients’ subcutaneous IG (SCIG) self-administration training, as part of a large survey by the Immune Deficiency Foundation (IDF).

METHODS: An online survey was sent to patients/their caregivers from the IDF database from March 10–31, 2017. Respondents were questioned regarding their experience of being trained to self-administer SCIG.

RESULTS: A total of 371 PI patients on SCIG responded to the survey, 63% were IVIG-transitioned and 37% has only been treated with SCIG; 18% were aged 30–44, 48% 45–64 and 17% ≥65. Sixty-one percent reported receiving 1–2 training sessions, 19% reported 3 sessions, and 20% required ≥4 sessions. Median duration of training sessions was 2 h (IQR 1–3 h); 78% were trained by home health care or specialty pharmacy staff, and 75% were trained at home. Ease of learning to self-administer, rated on a scale from 1 (worst) to 7 (best), was ≥6 for more than 70%; 44% reported a score of 7 while only 3% reported scores of 1 or 2. Ninety-five % reported that there are no insurance barriers to the number of training sessions, or they did not know of any barriers. When asked about concerns, 48% cited inserting the needle into the skin; 24% noted no concerns.

CONCLUSIONS: Survey results show a large majority of PI patients currently receiving SCIG reported minimal or no difficulty in learning self-administration. Combined with relatively short reported training time requirements, this suggests that with appropriate training, most patients easily learn SCIG self-administration.